Irradiation Overview Collaborative Group. N. Engl. J. Med., 341: 476 –
484, 1999.
10. Arnold, S. M., Young, A. B., Munn, R. K., Patchell, R. A.,
Hanayakkara, U., and Markesbery, W. R. Expression of p53, bcl-2,
E-cadherin, matrix metalloproteinase-9, and tissue inhibitor of metalloproteinases-1 in paired primary tumors and brain metastasis. Clin.
Cancer Res., 5: 4028–4033, 1999.
11. D'Amico, T. A., Aloia T. A., Moore, M-B. H., Conlon, D. H.,
Herndon, J. E., II, Kinch, M. S., and Harpole, Jr., D. H. Predicting the
sites of metastases from lung cancer using molecular biologic markers.
Ann. Thorac. Surg., 72: 1144 –11448, 2001.
12. Nicholson, R. I., Gee, J. M., and Harper, M. E. EGFR and cancer
prognosis. Eur. J. Cancer, 37 (Suppl. 4): S9 –S15, 2001.
13. Hida, T., Yatabe, Y., Achiwa, H., Muramatsu, H., Kozaki, K.,
Nakamura, S., Ogawa, M., Mitsudomi, T., Sugiura, T., and Takahashi,
T. Increased expression of cyclooxygenase 2 occurs frequently in hu-man lung cancers, specifically in adenocarcinomas. Cancer Res., 58:
3761–3764, 1998.
14. Wolff, H., Saukkomen, K., Auttila, S., Karjalainen, A., Vainio, H.,
and Ristima ̈ki, A. Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Res., 58: 4997–5001, 1998.
15. Achiwa, H., Yatabe, Y., Hida, T., Kuroishi, T., Kozaki, K., Nakamura, W., Ogawa, M., Sugiura, T., Mitsudomi, T., and Takahashi, T.
Prognostic significance of elevated cyclooxygenase 2 expression in
primary, resected lung adenocarcinomas. Clin. Cancer Res., 5: 1001–
1005, 1999.
16. Krajewski, S., Krajewski, M., Shabaik, A., Mujoshita, T., Wang,
H. G., and Reed, J. C. Immunohistochemical determination of in vivo
distribution of Bax, a dominant inhibitor of Bcl-2. Am. J. Pathol., 145:
1323–1336, 1994.
17. Rusch, V., Klimstra, D., Venkatraman, E., Pisters, P. W. T., Langenfeld, J., and Dmitrovsky, E. Overexpression of the epidermal growth
factor receptor and its ligand transforming growth factor is frequent in
resectable non-small cell lung cancer but does not predict tumor progression. Clin. Cancer Res., 3: 515–522, 1997.
18. Soslow, R. A., Dannenberg, A. J., Rush, D., Woerner, B. M., Khan,
K. N., Mosferrer, J., and Koki, A. T. COX-2 is expressed in human
pulmonary, colonic, and mammary tumors. Cancer (Phila.), 89: 2637–
2645, 2000.
19. Huang, C., Kohno, N., Inufusa, H., Kodama, K., Taki, T., and
Miyake, M. Overexpression of bax associated with mutations in the
loop-sheet-helix motif of p53. Am. J. Pathol., 155: 955–965, 1999.
20. Ohsaki, Y., Tamo, S., Fujita, Y., Toyoshima, E., Fujiuchi, S.,
Nishigski, Y., Ishida, S., Nagase, A., Miyokawa, N., Hirata, S., and
Kikuchi, K. Epidermal growth factor receptor expression correlates with
poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncol. Rep., 7: 603–607, 2000.
21. Caputi, M., Groeger, A. M., Esposito, V., De Luca, A., Murabito,
M., Tahir, T., Gordano, G. G., Baldi, F., Girodano, A., and Wolner, E.
Frequent high expression of bax pro-apoptotic protein in non-small cell
lung cancer. Anticancer Res., 19: 825–827, 1999.
22. Apolinario, R. M., van der Valk, P., de Jong, J. S., Deville, W.,
van Ark-Otte, J., Dingemans, A-M. C., van Mourik, J. C., Postmus,
P. E., Pinedo, H. M., and Giaccone, G. Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in
patients with radically resected non-small-cell lung cancer. J. Clin.
Oncol., 15: 2456 –2466, 1997.
23. Kroemer, G. The proto-oncogene Bcl-2 and its role in regulating
apoptosis. Nat. Med., 3: 614–620, 1997.
